Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CNTB
Upturn stock ratingUpturn stock rating

Connect Biopharma Holdings Ltd (CNTB)

Upturn stock ratingUpturn stock rating
$0.98
Last Close (24-hour delay)
Profit since last BUY3.16%
upturn advisory
Consider higher Upturn Star rating
BUY since 11 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: CNTB (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $6.5

1 Year Target Price $6.5

Analysts Price Target For last 52 week
$6.5Target price
Low$0.51
Current$0.98
high$1.6

Analysis of Past Performance

Type Stock
Historic Profit -58.1%
Avg. Invested days 12
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 55.56M USD
Price to earnings Ratio -
1Y Target Price 6.5
Price to earnings Ratio -
1Y Target Price 6.5
Volume (30-day avg) 2
Beta -0.27
52 Weeks Range 0.51 - 1.60
Updated Date 06/30/2025
52 Weeks Range 0.51 - 1.60
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.31

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -66.1%
Operating Margin (TTM) -81.69%

Management Effectiveness

Return on Assets (TTM) -12.47%
Return on Equity (TTM) -18.66%

Valuation

Trailing PE -
Forward PE 0.77
Enterprise Value -27493944
Price to Sales(TTM) 2.13
Enterprise Value -27493944
Price to Sales(TTM) 2.13
Enterprise Value to Revenue -
Enterprise Value to EBITDA 0.19
Shares Outstanding 55561100
Shares Floating 14373645
Shares Outstanding 55561100
Shares Floating 14373645
Percent Insiders 40.65
Percent Institutions 43.97

Analyst Ratings

Rating 2
Target Price 6.5
Buy 1
Strong Buy 1
Buy 1
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Connect Biopharma Holdings Ltd

stock logo

Company Overview

overview logo History and Background

Connect Biopharma Holdings Ltd. is a global clinical-stage biopharmaceutical company dedicated to developing therapies for chronic inflammatory diseases. Founded in 2012, it has focused on creating and advancing a pipeline of novel molecules targeting key pathways in immune-mediated disorders. The company went public but was taken private in 2023.

business area logo Core Business Areas

  • Drug Development: Researching, developing, and clinically testing novel therapeutic candidates for chronic inflammatory diseases.
  • Commercialization: Preparing for the potential commercialization of its drug candidates, pending regulatory approval.

leadership logo Leadership and Structure

Details about their executive team are not readily available due to its private status. Organizational structure information is similarly limited, reflecting its current stage as a research-driven company.

Top Products and Market Share

overview logo Key Offerings

  • CBP-201 (Itezolumab): A monoclonal antibody targeting IL-17 receptor A (IL-17RA), being developed for atopic dermatitis (AD) and asthma. Clinical trials are ongoing. Market share information is not publicly available due to its pre-commercialization status. Competitors include Sanofi (SNY) with Dupixent, and AbbVie (ABBV) with Rinvoq.
  • CBP-174: An oral peripherally acting antagonist of histamine receptor 3 (H3R) being developed for pruritus. Clinical trials are ongoing. Market share information is not publicly available. Competitors include Kiniksa Pharmaceuticals, and other pharmaceutical companies developing pruritus treatments.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry, particularly the segment focused on chronic inflammatory diseases, is characterized by high growth potential driven by the increasing prevalence of these conditions and advancements in immunology and targeted therapies. Competition is intense, with numerous companies vying to develop novel treatments.

Positioning

Connect Biopharma positions itself as an innovator in the field of inflammatory diseases, focusing on differentiated mechanisms of action and unmet medical needs. Its competitive advantage lies in its pipeline of novel molecules and its experienced management team.

Total Addressable Market (TAM)

The TAM for atopic dermatitis and asthma is estimated to be in the tens of billions of dollars. Connect Biopharma aims to capture a significant share of this market with its lead drug candidate, CBP-201, if approved.

Upturn SWOT Analysis

Strengths

  • Novel drug candidates targeting validated pathways
  • Experienced management team
  • Strong intellectual property portfolio

Weaknesses

  • Limited financial resources compared to larger pharmaceutical companies
  • High risk associated with drug development
  • Dependence on successful clinical trial outcomes

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion of pipeline through acquisitions or in-licensing
  • Regulatory approvals for its drug candidates

Threats

  • Competition from existing and emerging therapies
  • Clinical trial failures
  • Regulatory hurdles
  • Pricing pressures

Competitors and Market Share

competitor logo Key Competitors

  • SNY
  • ABBV
  • LLY
  • MRK
  • BMY
  • PFE

Competitive Landscape

Connect Biopharma faces intense competition from established pharmaceutical companies with approved therapies and robust pipelines. Its success depends on demonstrating superior efficacy and safety of its drug candidates.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by the advancement of its pipeline through preclinical and clinical development stages.

Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approvals for its drug candidates. Potential revenue streams from commercialization or partnerships could drive future growth.

Recent Initiatives: Recent initiatives include advancing CBP-201 and CBP-174 through clinical trials and exploring potential partnerships.

Summary

Connect Biopharma is a development-stage company with a promising pipeline of novel therapeutics for inflammatory diseases. While it faces significant challenges including competition and regulatory hurdles, its innovative approach and experienced team position it for potential success. Successful clinical trials and strategic partnerships are crucial for future growth and realizing value. With its current private ownership, it needs to focus on proving its pipeline's value to drive long term performance.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • ClinicalTrials.gov
  • Analyst Reports (where available, limited due to private status)
  • SEC Filings (historical prior to going private)

Disclaimers:

The information provided is based on publicly available data and analyst estimates. Accuracy is not guaranteed. This is not financial advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Connect Biopharma Holdings Ltd

Exchange NASDAQ
Headquaters San Diego, CA, United States
IPO Launch date 2021-03-19
CEO & Director Dr. Barry D. Quart Pharm.D.
Sector Healthcare
Industry Biotechnology
Full time employees 62
Full time employees 62

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.